BRIEF published on 08/10/2026 at 08:35, 2 months 18 days ago Innate Pharma Advances Lacutamab into Phase 3 Trial with Sobi Innate Pharma Lacutamab Phase 3 TELLOMAK-3 Markus Jensen Sobi Partnership
PRESS RELEASE published on 08/10/2026 at 08:30, 2 months 18 days ago Informations privilégiées / Autres communiqués Innate Pharma fait progresser Lacutamab vers la phase 3 suite au partenariat avec Sobi et nomme un nouveau directeur médical. Démarrage de l'étude TELLOMAK-3 pour le syndrome de Sézary Partenariat Phase 3 Innate Pharma Directeur Médical Lacutamab
BRIEF published on 05/19/2026 at 07:05, 5 months 9 days ago Innate Pharma to Attend Jefferies Global Healthcare Conference Biotechnology Cancer Treatment Immunotherapy Innate Pharma Jefferies Conference
BRIEF published on 05/19/2026 at 07:05, 5 months 9 days ago Innate Pharma at the Jefferies Global Healthcare Conference Immunotherapy Cancer Innate Pharma Therapeutic Antibodies Jefferies Conference
BRIEF published on 05/19/2026 at 07:05, 5 months 9 days ago Innate Pharma participera à la conférence mondiale sur les soins de santé de Jefferies Biotechnologie Immunothérapie Traitement Du Cancer Innate Pharma Conférence Jefferies
BRIEF published on 05/19/2026 at 07:05, 5 months 9 days ago Innate Pharma à la Conférence Jefferies Global Healthcare Immunothérapie Cancer Innate Pharma Conférence Jefferies Anticorps Thérapeutiques
PRESS RELEASE published on 05/19/2026 at 07:00, 5 months 9 days ago Inside Information / Other news releases Innate Pharma to participate in Jefferies Global Healthcare Conference on June 2-4, 2026 in New York, United States. Developing immunotherapies for cancer patients Biotechnology Innate Pharma Jefferies Global Healthcare Conference Immunothérapies Cancer Patients
PRESS RELEASE published on 05/19/2026 at 07:00, 5 months 9 days ago Informations privilégiées / Autres communiqués Innate Pharma participera à la conférence Jefferies Global Healthcare 2026 à New York. La société de biotechnologies développe des traitements d'immunothérapies contre le cancer Conference Cancer Innate Pharma Biotechnologies Immunothérapies
BRIEF published on 04/17/2026 at 21:05, 6 months 10 days ago Innate Pharma dévoile des résultats intermédiaires prometteurs dans l'étude de phase 2 MATISSE Essais Cliniques Cancer Du Poumon Innate Pharma MATISSE Phase 2 IPH5201
BRIEF published on 04/17/2026 at 21:05, 6 months 10 days ago Innate Pharma présente des résultats intermédiaires de l'essai MATISSE au congrès AACR Cancer Du Poumon Innate Pharma AACR 2026 IPH5201 Phase 2 MATISSE
Published on 10/28/2026 at 11:00, 11 minutes ago Banyan Extends Mineralization into the Airstrip–Powerline Gap at AurMac, Yukon, Intersects 1.34 g/t Au over 20.2 metres and 1.18 g/t Au over 27.5 metres
Published on 10/28/2026 at 08:00, 3 hours 11 minutes ago Algo Grande Copper Makes New Skarn Discovery at Adelita; Step-Out Hole AG-CG-PH2-003 Returns a Combined 139.81 Metres of 1.3% CuEq from Cerro Grande and the New Margarita Skarn
Published on 10/28/2026 at 02:55, 8 hours 16 minutes ago Challenger Underground MRE Doubles to 230koz @ 3.65 g/t Au
Published on 10/28/2026 at 02:50, 8 hours 21 minutes ago Letter to Shareholders Regarding Annual General Meeting
Published on 10/27/2026 at 23:40, 11 hours 31 minutes ago Second Closing of US$3.4 Million Private Placement
Published on 10/28/2026 at 11:06, 5 minutes ago You can only move fast if you know where you're going…
Published on 10/28/2026 at 11:05, 6 minutes ago New DJI Power Auro 2000 Elite Packs Car Charging and Solar Benefits Into DJI's Most Compact 2kWh Power Station
Published on 10/28/2026 at 11:00, 11 minutes ago FUCHS expands presence in Africa through strategic investments
Published on 10/28/2026 at 11:00, 11 minutes ago DEBRA Research Invests in Topadur to Advance Small-Molecule Therapies for Dystrophic Epidermolysis Bullosa
Published on 10/28/2026 at 11:00, 11 minutes ago DEBRA Research Invests in Topadur to Advance Small-Molecule Therapies for Dystrophic Epidermolysis Bullosa
Published on 10/28/2026 at 08:00, 3 hours 11 minutes ago Edenred successfully raises €800 million in a dual-tranche bond offering
Published on 10/28/2026 at 08:00, 3 hours 11 minutes ago Edenred lève avec succès 800 millions d’euros dans le cadre d’une émission obligataire à deux tranches
Published on 10/27/2026 at 18:00, 17 hours 11 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 22, 2026
Published on 10/27/2026 at 18:00, 17 hours 11 minutes ago Nombre total de droits de vote et actions composant le capital social au 22 octobre 2026
